clinical trial · NCT04476030
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Biogen·phase3·completed·n = 440
Depressive Disorder, MajorSAGE-217Matching PlaceboSertralineEscitalopramCitalopramDuloxetineDesvenlafaxine
brief summary
The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.
started
Nov 9, 2020
primary completion
Oct 25, 2021
completion
Dec 22, 2021
last updated
Dec 22, 2023
detailed description
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
official title
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol